We use AI to design antibodies for intractable diseases
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Fueled by partnerships and increasing demand for internal R&D, we will be looking to you to apply and develop ML-guided antibody design technologies in tight collaboration and feedback with our wet-lab. This will include:
A typical interview process looks something like:
We aim to keep our process efficient and not waste either of our time. The whole process can be done in 2-3 weeks.
Antibodies need to possess a multitude of properties to be manufacturable, safe, and efficacious for patients. This is a hard engineering problem with a high a failure rate, because today’s discovery technologies rely on brute-force guess-and-check. At Nabla, we're building a protein design platform that enables us to build antibodies deliberately, with all the properties they need to reach and treat patients, and do so faster than we can today.
Learn more at: https://www.nabla.bio/